Stability of MRD-PCR targets in patients with monoclonal and oligoclonal Ig and TCR gene configuration
| . | Stability of MRD-PCR targets . | Stability in patients (all l ≥ 1) . | ||||
|---|---|---|---|---|---|---|
| Monoclonal . | Oligoclonal . | Total . | Monoclonal . | Oligoclonal . | Total . | |
| IGH | ||||||
| VH-JH | 88% | 47% | 69% | 81%/98% | 37%/73% | 63%/88% |
| (n = 67) | (n = 60) | (n = 127) | ||||
| DH-JH | 57% | 38% | 43% | 67%/67% | 27%/53% | 33%/57% |
| (n = 7) | (n = 21) | (n = 28) | ||||
| All | 85% | 44% | 64% | 76%/98% | 24%/76% | 52%/88% |
| (n = 74) | (n = 81) | (n = 155) | (n = 42) | (n = 33) | (n = 75) | |
| IGK-Kde | ||||||
| Vκ-Kde | 95% | 40% | 91% | 94%/97% | 33%/66% | 88%/94% |
| (n = 39) | (n = 5) | (n = 44) | ||||
| Intron-Kde | 86% | 0% | 87% | 92%/92% | 0% | 85%/85% |
| (n = 15) | (n = 15) | |||||
| All* | 95% | 40% | 90% | 95%/95% | 33%/66% | 88%/93% |
| (n = 55) | (n = 5) | (n = 60) | (n = 37) | (n = 3) | (n = 40) | |
| TCRG | ||||||
| Vγ-Jγ | ND | ND | 75% | ND | ND | 64%/83% |
| (n = 87) | (n = 53) | |||||
| TCRD | ||||||
| Dδ2-Dδ3 | 100% | 14% | 63% | 100% | 14%/14% | 60%/60% |
| (n = 9) | (n = 7) | (n = 16) | ||||
| Vδ2-Dδ3 | 81% | 31% | 63% | 75%/80% | 20%/50% | 59%/71% |
| (n = 27) | (n = 16) | (n = 43) | ||||
| All† | 86% | 26% | 63% | 80%/88% | 14%/36% | 56%/69% |
| (n = 37) | (n = 23) | (n = 60) | (n = 25) | (n = 14) | (n = 39) | |
| . | Stability of MRD-PCR targets . | Stability in patients (all l ≥ 1) . | ||||
|---|---|---|---|---|---|---|
| Monoclonal . | Oligoclonal . | Total . | Monoclonal . | Oligoclonal . | Total . | |
| IGH | ||||||
| VH-JH | 88% | 47% | 69% | 81%/98% | 37%/73% | 63%/88% |
| (n = 67) | (n = 60) | (n = 127) | ||||
| DH-JH | 57% | 38% | 43% | 67%/67% | 27%/53% | 33%/57% |
| (n = 7) | (n = 21) | (n = 28) | ||||
| All | 85% | 44% | 64% | 76%/98% | 24%/76% | 52%/88% |
| (n = 74) | (n = 81) | (n = 155) | (n = 42) | (n = 33) | (n = 75) | |
| IGK-Kde | ||||||
| Vκ-Kde | 95% | 40% | 91% | 94%/97% | 33%/66% | 88%/94% |
| (n = 39) | (n = 5) | (n = 44) | ||||
| Intron-Kde | 86% | 0% | 87% | 92%/92% | 0% | 85%/85% |
| (n = 15) | (n = 15) | |||||
| All* | 95% | 40% | 90% | 95%/95% | 33%/66% | 88%/93% |
| (n = 55) | (n = 5) | (n = 60) | (n = 37) | (n = 3) | (n = 40) | |
| TCRG | ||||||
| Vγ-Jγ | ND | ND | 75% | ND | ND | 64%/83% |
| (n = 87) | (n = 53) | |||||
| TCRD | ||||||
| Dδ2-Dδ3 | 100% | 14% | 63% | 100% | 14%/14% | 60%/60% |
| (n = 9) | (n = 7) | (n = 16) | ||||
| Vδ2-Dδ3 | 81% | 31% | 63% | 75%/80% | 20%/50% | 59%/71% |
| (n = 27) | (n = 16) | (n = 43) | ||||
| All† | 86% | 26% | 63% | 80%/88% | 14%/36% | 56%/69% |
| (n = 37) | (n = 23) | (n = 60) | (n = 25) | (n = 14) | (n = 39) | |